Evidence map›Paper›PMID 36980717›Full record

ArticleCancers2023

Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways and

Jerry Xiao, Utsav Sharma, Abolfazl Arab, Sohit Miglani, Sonakshi Bhalla, Shravanthy Suguru, Robert Suter, Reetu Mukherji, Marc E Lippman, Paula R Pohlmann and 8 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jerry XiaoSchool of Medicine, Georgetown University, Washington, DC 20057, USA.ORCID 0000-0001-8315-1178
Utsav SharmaLombardi Cancer Center, Georgetown University, Washington, DC 20057, USA.
Abolfazl ArabDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-0024-2937
Sohit MiglaniDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-8075-320X
Sonakshi BhallaDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA.
Shravanthy SuguruDepartment of Pathology, Center for Cell Reprogramming, Georgetown University, Washington, DC 20057, USA.
Robert SuterLombardi Cancer Center, Georgetown University, Washington, DC 20057, USA.ORCID 0000-0002-3335-8426
Reetu MukherjiDepartment of Medicine, The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Medical Center, Washington, DC 20057, USA.ORCID 0000-0001-7384-0498
Marc E LippmanLombardi Cancer Center, Georgetown University, Washington, DC 20057, USA.
Paula R PohlmannLombardi Cancer Center, Georgetown University, Washington, DC 20057, USA.
Jay C ZeckDepartment of Pathology, Georgetown University Medical Center, Washington, DC 20057, USA.
John L MarshallDepartment of Medicine, The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Medical Center, Washington, DC 20057, USA.
Benjamin A WeinbergDepartment of Medicine, The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Medical Center, Washington, DC 20057, USA.
Aiwu Ruth HeDepartment of Medicine, The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Medical Center, Washington, DC 20057, USA.
Marcus S NoelDepartment of Medicine, The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown University Medical Center, Washington, DC 20057, USA.
Richard SchlegelDepartment of Pathology, Center for Cell Reprogramming, Georgetown University, Washington, DC 20057, USA.
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158, USA.
Seema AgarwalDepartment of Pathology, Center for Cell Reprogramming, Georgetown University, Washington, DC 20057, USA.ORCID 0000-0002-8854-252X

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
NCI NIH HHS P30 CA051008NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

Circulating tumor cells (CTCs), a population of cancer cells that represent the seeds of metastatic nodules, are a promising model system for studying metastasis. However, the expansion of patient-derived CTCs ex vivo is challenging and dependent on the collection of high numbers of CTCs, which are ultra-rare. Here we report the development of a combined CTC and cultured CTC-derived xenograft (CDX) platform for expanding and studying patient-derived CTCs from metastatic colon, lung, and pancreatic cancers. The propagated CTCs yielded a highly aggressive population of cells that could be used to routinely and robustly establish primary tumors and metastatic lesions in CDXs. Differential gene analysis of the resultant CTC models emphasized a role for NF-κB, EMT, and TGFβ signaling as pan-cancer signaling pathways involved in metastasis. Furthermore, metastatic CTCs were identified through a prospective five-gene signature (

Indexed as

CDX modelcirculating tumor cellscolon cancerlung cancermetastatic cancerpancreatic cancer

Identifiers

PMID36980717
PMCPMC10046547

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read59
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.